The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.

[1]  R. Rosell,et al.  Mechanisms of resistance to osimertinib , 2020, Journal of thoracic disease.

[2]  M. Ahn,et al.  TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Giovannetti,et al.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.

[4]  H. Hou,et al.  Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis , 2019, BMC Cancer.

[5]  V. Papadimitrakopoulou,et al.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.

[6]  M. Mino‐Kenudson,et al.  EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Sharyn I. Katz,et al.  Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.

[8]  Young Hak Kim,et al.  Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  L. Roisman,et al.  The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell‐Free DNA in Advanced Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Paul Baas,et al.  Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  B. Besse,et al.  Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? , 2018, Nature Reviews Clinical Oncology.

[12]  Yong He,et al.  Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. , 2018, Lung cancer.

[13]  Yunpeng Liu,et al.  Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients , 2018, Clinical Cancer Research.

[14]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[15]  S. Mortimer,et al.  The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients , 2017, Clinical Cancer Research.

[16]  Yi-long Wu,et al.  Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First‐ and Third‐Generation EGFR TKIs and Shifts Allelic Configuration at Resistance , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  H. Do,et al.  Combination Osimertinib and Gefitinib in C797S and T790M EGFR‐Mutated Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Thomas John,et al.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Gandara,et al.  Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  M. Varella‐Garcia,et al.  Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  C. Azzoli,et al.  MET amplification (amp) as a resistance mechanism to osimertinib. , 2017 .

[22]  ping wang,et al.  Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer , 2017, Oncotarget.

[23]  S. Kobayashi,et al.  Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. , 2017, Lung cancer.

[24]  Yasushi Okuno,et al.  Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer , 2017, Nature Communications.

[25]  Chia-Chi Lin,et al.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Shuhang Wang,et al.  EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. , 2017, Cancer letters.

[27]  Shuhang Wang,et al.  Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors , 2016, Frontiers of Medicine.

[28]  Matthew Grist,et al.  Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity , 2016, Clinical Cancer Research.

[29]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[30]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[31]  S. Fujita,et al.  EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer , 2015, Cancer Chemotherapy and Pharmacology.

[32]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[33]  M. Denis,et al.  EGFR T790M resistance mutation in non small-cell lung carcinoma. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[34]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.